A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

Oncologist - United States
doi 10.1634/theoncologist.2017-0664
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Cancer
Cancer ResearchOncology
2010English

A Randomized Phase II Study Evaluating Different Maintenance Schedules of Nab-Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer: Final Results of the IBCSG 42-12/Big 2-12 SNAP Trial

Annals of Oncology
MedicineOncologyHematology
2018English

Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Role of Nab-Paclitaxel in Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Oncotarget
Oncology
2017English

Comparative Effectiveness of Early-Line Nab-Paclitaxel vs. Paclitaxel in Patients With Metastatic Breast Cancer: A US Community-Based Real-World Analysis

Cancer Management and Research
Oncology
2018English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Chromosome 17 Polysomy Without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared With Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Individually Tailored Treatment With Epirubicin and Paclitaxel With or Without Capecitabine as First-Line Chemotherapy in Metastatic Breast Cancer: A Randomized Multicenter Trial

Breast Cancer Research and Treatment
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy